205 related articles for article (PubMed ID: 36318701)
1. Real-world treatment patterns and use of adjunctive pain and anti-inflammatory medications among patients with psoriatic arthritis treated with IL-17A inhibitors in the United States.
Pizzicato LN; Vadhariya A; Birt J; Ketkar AG; Bolce R; Grabner M; Pepe RS; Walsh JA
J Manag Care Spec Pharm; 2023 Jan; 29(1):24-35. PubMed ID: 36318701
[No Abstract] [Full Text] [Related]
2. Comparison of Health Care Costs Among Patients with Psoriasis Initiating Ixekizumab, Secukinumab, or Adalimumab.
Blauvelt A; Shi N; Zhu B; Burge R; Malatestinic WN; Lin CY; Lew CR; Zimmerman NM; Goldblum OM; Murage MJ
J Manag Care Spec Pharm; 2019 Dec; 25(12):1366-1376. PubMed ID: 31778621
[TBL] [Abstract][Full Text] [Related]
3. Treatment patterns and health care costs among patients with psoriatic arthritis treated with biologic or targeted synthetic disease-modifying antirheumatic drugs.
Murage MJ; Princic N; Park J; Malatestinic WN; Zhu B; Atiya B; Kern SA; Stenger KB; Sprabery AT; Ogdie A
J Manag Care Spec Pharm; 2022 Feb; 28(2):206-217. PubMed ID: 35098751
[No Abstract] [Full Text] [Related]
4. Real-world persistence and costs among patients with chronic migraine treated with onabotulinumtoxinA or calcitonin gene-related peptide monoclonal antibodies.
Schwedt TJ; Lee J; Knievel K; McVige J; Wang W; Wu Z; Gillard P; Shah D; Blumenfeld AM
J Manag Care Spec Pharm; 2023 Oct; 29(10):1119-1128. PubMed ID: 37776119
[No Abstract] [Full Text] [Related]
5. Treatment Patterns Among Patients with Psoriatic Arthritis Treated with a Biologic in the United States: Descriptive Analyses from an Administrative Claims Database.
Walsh JA; Adejoro O; Chastek B; Palmer JB; Hur P
J Manag Care Spec Pharm; 2018 Jul; 24(7):623-631. PubMed ID: 29952704
[TBL] [Abstract][Full Text] [Related]
6. Patient Support Program Increased Medication Adherence with Lower Total Health Care Costs Despite Increased Drug Spending.
Brixner D; Rubin DT; Mease P; Mittal M; Liu H; Davis M; Ganguli A; Fendrick AM
J Manag Care Spec Pharm; 2019 Jul; 25(7):770-779. PubMed ID: 31081461
[TBL] [Abstract][Full Text] [Related]
7. Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis.
Rubin DT; Mittal M; Davis M; Johnson S; Chao J; Skup M
J Manag Care Spec Pharm; 2017 Aug; 23(8):859-867. PubMed ID: 28737994
[TBL] [Abstract][Full Text] [Related]
8. Comparison of real-world treatment patterns among patients with psoriasis prescribed ixekizumab or secukinumab.
Blauvelt A; Shi N; Burge R; Malatestinic WN; Lin CY; Lew CR; Zimmerman NM; Goldblum OM; Zhu B; Murage MJ
J Am Acad Dermatol; 2020 Apr; 82(4):927-935. PubMed ID: 31712178
[TBL] [Abstract][Full Text] [Related]
9. Patient Characteristics, Health Care Resource Utilization, and Costs Associated with Treatment-Regimen Failure with Biologics in the Treatment of Psoriasis.
Foster SA; Zhu B; Guo J; Nikai E; Ojeh C; Malatestinic W; Goldblum O; Kornberg LJ; Wu JJ
J Manag Care Spec Pharm; 2016 Apr; 22(4):396-405. PubMed ID: 27023693
[TBL] [Abstract][Full Text] [Related]
10. Adherence to therapy of ixekizumab and secukinumab in psoriatic arthritis patients using first- or second-line IL-17A inhibitor treatment: a Danish population-based cohort study.
Hansen RL; Jørgensen TS; Egeberg A; Rosenø NAL; Skougaard M; Stisen ZR; Dreyer L; Kristensen LE
Rheumatology (Oxford); 2024 May; 63(6):1593-1598. PubMed ID: 37647648
[TBL] [Abstract][Full Text] [Related]
11. Real-World Persistence and Treatment Patterns in Patients with Psoriatic Arthritis Treated with Anti-IL17 Therapy in Spain: The PerfIL-17 Study.
Joven B; Manteca CF; Rubio E; Raya E; Pérez A; Hernández R; Manrique S; Núñez M; Díaz-Cerezo S; Moyano S; Lacetera A; García-Vicuña R
Adv Ther; 2023 Dec; 40(12):5415-5431. PubMed ID: 37804475
[TBL] [Abstract][Full Text] [Related]
12. Cost per cumulative clinical benefit of biologic therapies for patients with plaque psoriasis: a systematic review.
Blauvelt A; Burge R; Malatestinic W; Brnabic A; Guo J; Janardhanan M; Zhu B
J Manag Care Spec Pharm; 2021 Jan; 27(1):84-94. PubMed ID: 33377444
[No Abstract] [Full Text] [Related]
13. Patient characteristics associated with use of TNF vs interleukin inhibitors as first-line biologic treatment for psoriatic arthritis.
Jin Y; Chen SK; Lee H; Landon JE; Merola JF; Kim SC
J Manag Care Spec Pharm; 2021 Aug; 27(8):1106-1117. PubMed ID: 34337987
[No Abstract] [Full Text] [Related]
14. Incidence of Serious Infections and Design of Utilization and Safety Studies for Biologic and Biosimilar Surveillance.
Zhang J; Sridhar G; Barr CE; Eichelberger B; Lockhart CM; Marshall J; Clewell J; Accortt NA; Curtis JR; Holmes C; McMahill-Walraven CN; Brown JS; Haynes K
J Manag Care Spec Pharm; 2020 Apr; 26(4):417-490. PubMed ID: 32223608
[TBL] [Abstract][Full Text] [Related]
15. Annual costs among patients with major depressive disorder and the impact of key clinical events.
Cutler AJ; Keyloun KR; Higa S; Park J; Bonafede M; Gillard P; Jain R
J Manag Care Spec Pharm; 2022 Dec; 28(12):1335-1343. PubMed ID: 36427344
[No Abstract] [Full Text] [Related]
16. Comparison of two-year treatment adherence, persistence, discontinuation, reinitiation, and switching between psoriasis patients treated with ixekizumab or secukinumab in real-world settings.
Blauvelt A; Shi N; Somani N; Burge R; Zhu B; Ridenour TL; Lew CR; Zimmerman NM; Atiya B; Murage MJ
J Am Acad Dermatol; 2022 Mar; 86(3):581-589. PubMed ID: 34252464
[TBL] [Abstract][Full Text] [Related]
17. Health care utilization and costs associated with functional status in patients with psoriatic arthritis.
Ogdie A; Hwang M; Veeranki P; Portelli A; Sison S; Shafrin J; Pedro S; Hass S; Hur P; Kim N; Yi E; Michaud K
J Manag Care Spec Pharm; 2022 Sep; 28(9):997-1007. PubMed ID: 36001101
[No Abstract] [Full Text] [Related]
18. Sustained long-term benefits of patient support program participation in immune-mediated diseases: improved medication-taking behavior and lower risk of a hospital visit.
Fendrick AM; Brixner D; Rubin DT; Mease P; Liu H; Davis M; Mittal M
J Manag Care Spec Pharm; 2021 Aug; 27(8):1086-1095. PubMed ID: 33843252
[No Abstract] [Full Text] [Related]
19. Characteristics and Medication Use of Psoriasis Patients Who May or May Not Qualify for Randomized Controlled Trials.
Malatestinic W; Nordstrom B; Wu JJ; Goldblum O; Solotkin K; Lin CY; Kistler K; Fraeman K; Johnston J; Hawley LL; Sicignano N; Araujo A
J Manag Care Spec Pharm; 2017 Mar; 23(3):370-381. PubMed ID: 28230450
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]